William Greene

Chief Investment Officer
2022
Hevolution Foundation is a non-profit organization that awards grants and early-stage investments to support research and entrepreneurship in the emerging fields of geroscience and healthspan research.

2021 - 2022

Chief Executive Officer
2021 - 2022
Actionable Drug Discovery AI; Targeting cellular age itself to treat chronic degenerative diseases. Built Company, raised VC financing, initiated drug discovery and development effort, expanded platform into neuroscience and immunology. Attracted Pharma investor/partner.

2014 - 2022

Chariman and CEO
2014 - 2022
Oversaw all corporate, development, and medical/scientific operations of the Company, which is developing targeted therapies for age-related macular degeneration, cancer and other serious diseases. Grew from virtual beginnings to an integrated research and development organization. ...Raised > $100M in funding ...Transitioned company from academic spinout to fully functional professionally-led biotechnology company encompassing discovery, research, and clinical development ...Grew company from sole focus on one ophthalmology project to include oncology development and inflammation research ...Led clinical development team, completed 3 clinical trials, re-invigorated intellectual property with multiple patent filings (including authorship of IP) ...Expanded product pipeline from single in-licensed product to full suite of molecules invented by Company scientists ...Completed two marquee Pharma deals ...Successfully completed M&A exit with solid up-front return to investors and significant milestones

2013 - 2022

Member Board Of Directors, Chairman of Investment Committee
2013 - 2022
GHIF is a $110M impact venture capital fund focused on the development, manufacture and commercialization of therapies, products and services to further global health and neglected diseases. Supported by the Bill and Melinda Gates Foundation. As the Board’s Founding Chairman, assisted in structuring and raising the Fund, acting as liaison between the investing team and the rest of the Board and managing the Investment Committee which oversees and approves all investment proposals. Pioneering effort to engage strategic and financial partners in global health investing, at scale.

2019 - 2021

Board Member
2019 - 2021
Company developing novel T-cell engager platform for immuno-oncology. Highly successful M&A exit to Takeda.

2002 - 2019

Venture Partner
2012 - 2019
MPM Capital, LLP, is an internationally known life sciences venture capital firm with several billion dollars under management.
Managing Director
2002 - 2012
Experience leading all aspects of company diligence, investment analysis, deal structuring, portfolio company management and fund strategy. Investment experience in biotechnology (small and large molecules), vaccines, medical devices and pharma services. Build highly successful management teams from start-up through exit. In addition to Board membership, have served significant development advisory roles for portfolio companies including Interim VP Regulatory, Interim CMO, and Clinical Development Advisor to several companies. US, European and Asian (India) experience Broad and deep Board experience including IPOs, M&A exits.

2013 - 2016

Co-Founder
2013 - 2016
Pioneering Prescription Digital Therapeutics. Co-founded Company; developed clinical/regulatory strategy.

1999 - 2006

Assistant Clinical Professor of Medicine
1999 - 2006
Attending Physician, Internal Medicine service at San Francisco General Hospital. Cared for patients, taught, and mentored students and residents.

1998 - 2002

Senior Clinical Scientist and Epidemiologist
1998 - 2002
Clinical Science: designed, implemented and analyzed clinical trials in several therapeutic areas at all stages of development, including leading interactions with regulatory agencies and investigators, developing and presenting data internally and externally, and creating publication strategies. Led the early clinical development of Lucentis for Age-Related Macular Degeneration, major contribution to clinical development of Raptiva. Wide therapeutic area experience including cardiovascular disease, vascular biology, ophthalmology, respiratory disease and gastroenterology across Phases 0-4. Epidemiology: population science, innovative trial methods, drug safety evaluation and market analysis. Collaborated with Research, Medical Affairs, Regulatory Affairs and Marketing functions.

Dynamic, Experienced Biotech Investor, CEO, Drug Developer